Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The study will assess the safety, tolerability and pharmacokinetics of single intravenous
(IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour
infusion.